*Breast Cancer Research and Treatment* **28**: 301, 1993.
© 1993 *Kluwer Academic Publishers. Printed in the Netherlands.*

## Author index, Volume 28


Abeloff MD 277
Amadori A 251
Amadori D 251
Anderson DE 107
Angioli R 21
Armstrong DK 277
Averette HE 21

Badzioch MD 107
Baum M 241
Beardslee S 9
Beer DG 267
Bertoni L 251
Bitran JD 291
Blamey RW 299
Bondy ML 137
Bowcock AM 121

Casanova S 251
Castellani R 261
Charreau EH 29
Chau TC 21
Clark GM 9
Claus EB 115

Danø K 223
Davidson NE 277
De Giovanni C 251
De Paola F 251
Dosne Pasqualini C 29
Dowsett M 241
Dran G 29
Dupont WD 157

Ethier SP 267
Eto T 41

Fetting JH 277
Flamigni A 251
Frank TS 267

Galea MH 299
Gilchrist KW 1
Giulotto E 251
Gordon GB 277
Gray R 1
Griggs LJ 241
Grøndahl-Hansen J 223

Hähnel E 295
Hähnel R 295
Halabi S 136
Harai K 231
Harrington D 9
Haynes BP 241
Hidaka O 41
Higginbotham E 195
Huelskamp AM 277
Huffman S 291
Hussain ME 261

Imanishi Y 231
Inui H 231
Itoh K 215
Itoh Y 215
Iwase H 215
Iwata H 215

Jarman M 241
Johnston SRD 241

Kanematsu T 41
Kobayashi S 215
Koechli OR 21
Kordon EC 29
Kurooka K 231
Kuzushima T 215

Lanari C 29
Lantz PM 97
Lerman C 145

Mahacek ML 267
Masaoka A 215
Matsuo S 41
McGuire WL 9
McKinna JA 241
Mesker WE 1
Mick R 291
Miyazaki J 41
Molinolo AA 29
Myers SE 291

Nagayama K 231
Naito A 215
Namer M 69
Newcomb PA 97

Ohara O 41
Oldaker T 9
Owens MA 9
Ozaka M 231

Page DL 157
Pandian MR 9
Pasqualini CD
*see* Dosne Pasqualini C
Pazos P 29
Perras JP 21
Pike MC 179
Ploem JS 1
Ploem-Saaijer JJ 1
Pounds G 9

Risch N 115
Robbins P 295
Rosenquist C 223

Sacks NPM 241
Santos O 285

Sarkar FH 261
Savini S 251
Schwartz M 145
Sellin
*see* Vassilopoulou-Sellin
Sevin B-U 21
Smith IE 241
Soejima H 41
Spicer DV 179
Steren A 21

Taylor SG 1
Thompson WD 115
Thorpe SM 223
Tormey DC 1
Tsunoda T 41

Untch M 21

van Driel-Kulker AMJ 1
Vassilopoulou-Sellin R 167
Vendely P 9
Vernon SW 137
Visscher DW 261
Vogel VG 91,137,195

Wada T 231
Watatani M 231
Wenger CR 9
Williams SF 291
Wykes SM 261

Yamashita H 215
Yamashita T 215
Yasutomi M 231
Yeomans A 195

Zoli W 251

*Breast Cancer Research and Treatment* **28**: 303-308, 1993.
© 1993 *Kluwer Academic Publishers. Printed in the Netherlands.*

## Subject index, Volume 28

1,25-dihydroxycholecalciferol ($1,25[OH]_2D_3$)
*see* vitamin $D_3$
5-fluorouracil
in MVF induction regimen prior to high-dose therapy 291-294

adjustment, psychological
to improve screening adherence 145-155
adjuvant chemotherapy
effects on immunological parameters 85
more effective in ER+, PgR+ tumors 85
adriamycin
*see* doxorubicin
age
vs. ploidy and S-phase in >127,000 patients 9-20
aneuploidy
*see* ploidy
antibody engineering
report of Workshop on Breast Cancer Research and Immunology 285-290
antiestrogens
4-OH-Tam induction of cathepsin D in Tam-resistant cells 76
anti EGF, IGF-I actions in breast cancer cells 73
droloxifene, phase II trial 75
EGIS-5650 interactions with ER 77
endometrial carcinoma after tamoxifen regimen 86
hydroxytamoxifen isomerization and effects on normal breast cells 74
ICI 164,384 promotes ER degradation 72
long-term toremifene 87
modulation of growth-factor-induced genes 76
panomifene (EGIS-5650) pharmacokinetics 87
pulmonary embolism during adjuvant tamoxifen 87
tamoxifen best in PgR+, high S-phase 87
tamoxifen regulation of estrone sulfatase 77
tamoxifen sensitivity and resistance 73
tamoxifen treatment combination with β-interferon 88
tamoxifen tumor concentration vs. de novo resistance, ER status 241-250
antigens in breast cancer
report of Workshop on Breast Cancer Research and Immunology 285-290
antiprogestins
action of onapristone 74
aromatase inhibitors
4-hydroxyandrostenedione after aminoglutethimide 76
hydrocortisone contribution to aminoglutethimide activity 86
atypical hyperplasia
and risk of invasive breast cancer 157-166

breast cancer gene BRCA1
gene mapping techniques and strategy 121-135
breast cancer precursors
histologic and cytologic indicators of increased risk 157-166
BT-20 cells
ATP-cell-viability assay, taxol/doxorubicin combination 21-27

cancer control
factors in breast cancer risk perception 137-144
cancer vaccines
report of Workshop on Breast Cancer Research and Immunology 285-290
carcinoembryonic antigen (CEA)
in cyst fluid — diagnosis of intracystic carcinoma 41-44
carcinogenesis
progesterone vs. MPA induction of mammary tumors in mice 29-40
cathepsin D
estrogen response of gene 76
regulation and association with metastasis 71

cell lines
BRC-230 origin, markers, and multidrug resistance 251-260
metastatic lymph node line not immortalized 267-276
chemoprevention
prospects, and role of tamoxifen 75
chemosensitivity testing
ATP-cell-viability assay, taxol/doxorubicin combination 21-27
chemotherapy
16-week dose-intense regimen for locally advanced breast cancer 277-284
farmorubicin/oncovin/methylprednisolone after anthracycline 85
interferon-α/5-FU/tamoxifen 86
MVF induction regimen prior to high-dose therapy 291-294
chromosome 17
LOH analysis vs. aneuploidy, erbB-2 amplification 231-239
chromosome mapping
17q and the familial breast/ovarian cancer gene 121-135
chromosome rearrangements
in genetic evolution of breast cancer, with ER and PgR loss 72
clinical management
of high risk women 195-210
contraceptives
formulation for breast cancer protection 179-193
counseling
communicating risk assessments 195-210
on breast cancer risk 91-96
cyst fluid
CEA and diagnosis of intracystic carcinoma 41-44
ferritin, Zn, and cholesterol levels vs. risk 82
significance of steroid content 82

dietary modification
in management of high risk women 195-210
DNA content
by image cytometry, and prognosis 1-8
DNA Cytometry Consensus Conference
commentary on DNA flow cytometry in breast cancer 51-53
consensus statement for breast cancer 55-59
guidelines for implementation of DNA cytometry 61-68
doxorubicin
with taxol in *in vitro* sensitivity testing 21-27
drug sensitivity assay
ATP-cell-viability assay, taxol/adriamycin combination 21-27
ductal carcinoma in situ
and risk of invasive breast cancer 157-166
ductal vs. lobular carcinomas
MPA vs. progesterone induction in mice 29-40

early detection
and recent trends in breast cancer incidence 97-106
endometrial cancer
and family risk of breast cancer 107-113
epidermal growth factor receptor (EGFR)
by enzyme immunoassay (EIA) — prognostic value 215-221
by PCR in human breast tumor biopsies 81
comparison of assay methods 215-221
with p53, erbB-2 in prognosis 261-266
erbB-2 oncogene
*see* HER-2/neu oncogene
estrogen receptor
and EGF receptor status 215-221
effect on tumor concentrations of tamoxifen 241-250
regulation in breast cancer cells 73
vs. aneuploidy and number of nodes in prognosis 1-8
vs. ploidy and S-phase for prognosis in >25,000 patients 9-20
vs. tumor aggressiveness in young and old patients 81
estrogen replacement therapy
implications in high risk patients 195-210
in women at high risk for breast cancer 167-177
estrogen sulfatases
role in controlling tumor estrogen levels 72
estrogen-regulated genes
pBCL1 depressed by estrogens in breast cancer cells 73
expression in human tumor specimens 80

estrogens
in oral contraceptives, as breast mitogens 179-193
estrone sulfatase
regulation by tamoxifen 77
ethical considerations
in risk assessment and interventions 195-210

familial breast cancer
and risk evaluation 91-96
ovarian cancer association 115-120
risk effects of prostate, ovarian, and other familial cancers 197-113
familial breast/ovarian cancer gene BRCA1
gene mapping techniques and strategy 121-135
family history
psychological distress as a barrier to screening adherence 145-155
fine needle aspiration
histologic and cytologic indicators of risk 157-166
flow cytometry
DNA Cytometry Consensus Conference 51-68
ploidy and S-phase vs. relapse in >25,000 patients 9-20

genetics
and breast cancer risk assessment 97-210
chromosome 17 LOH vs. aneuploidy, erbB-2 amplification 231-239
gonadotropin releasing hormone (GnRH)
in contraceptive formulation for breast cancer protection 179-193

health-related behavior
factors in breast cancer risk perception 137-144
heart disease
and estrogen replacement therapy in women at high breast cancer risk 167-177
heparin-binding growth factors
role in malignant progression 71
HER-2/neu (erbB-2) oncogene
a new intronic polymorphism 45-49
amplification vs. chromosome 17 LOH 231-239
and EGFR in prognosis 215-221
in vitro biological effects of overexpression 71
target of recombinant immunotoxin 72
with p53, EGFR in prognosis 261-266
hormone dependence
in MPA vs. progesterone induced mammary tumors in mice 29-40
Hormones and Breast Cancer — symposium
abstracts 71-88
introduction 69
hyperplastic lesions
and risk of invasive breast cancer 157-166

image cytometry
DNA content and prognosis in node-positive breast cancer 1-8
imaging
report of Workshop on Breast Cancer Research and Immunology 285-290
steroid labelling with $^{18}F$ and $^{99m}Tc$ 78
immortalization
absent in a cell line from a metastatic lymph node 267-276
immunotherapy
report of Workshop on Breast Cancer Research and Immunology 285-290
immunotoxins
targeting HER-2/neu 72
incidence of breast cancer
recent trends 97-106
inflammatory breast cancer
16-week dose-intense regimen 277-284
insulin-like growth factor I (IGF-I)
reduction with somatostatin analog, no clinical response 84
interferon-β
treatment combination with tamoxifen 88
interleukin-2 receptor
on peripheral blood mononuclear cells in cancer patients 82
intracystic carcinoma of the breast
CEA in cyst fluid and diagnosis — case report 41-44

LHRH agonists
additive inhibition with MPA of rat DMBA tumors 78
LHRH analogs
decapeptyl (D-Trp-6) phase II trial 84
in breast cancer treatment 75
lobular vs. ductal carcinomas
progesterone vs. MPA induction in mice 29-40

locally advanced breast cancer
16-week dose-intense regimen 277-284
loss of heterozygosity
analysis of chromosome 17 in breast cancer 231-239

mammography
*see* screening
markers
report of Workshop on Breast Cancer Research and Immunology 285-290
sialic acid and fibronectin 83
MCF-7 cells
ATP-cell-viability assay, taxol/doxorubicin combination 21-27
inhibiting and stimulating factors tested in serum-free medium 79
medroxyprogesterone acetate (MPA)
additive inhibition with LHRH agonist of rat DMBA tumors 78
dose response and toxicity in advanced breast cancer 74
high-dose — adjustment by monitoring serum levels 88
improved tolerance of AVCF chemotherapy 84
myeloprotective activity 85
vs. progesterone in inducing mammary tumors in mice 29-40
menopause
after breast cancer treatment — estrogen replacement therapy 167-177
mitoxantrone
in MVF induction regimen prior to high-dose therapy 291-294
molecular biology techniques
mapping the familial breast/ovarian cancer gene BRCA1 121-135
molecular markers
in node-negative breast tumors 82
mortality from breast cancer
recent trends 97-106
mucins in breast cancer
report of Workshop on Breast Cancer Research and Immunology 285-290
myc oncogene
estrogen and antiestrogen regulation in normal breast cells 77
in MCF-7 cell regulation 77

nodal status
number of positive nodes and prognosis 1-8
vs. ploidy and S-phase in >127,000 patients 9-20

oncogenes
a new HER-2/neu intronic polymorphism 45-49
opioid peptides
in human breast tumor cells and stroma 83
osteoporosis
and estrogen replacement therapy in women at high breast cancer risk 167-177
ovarian cancer
and familial breast cancer risk 115-120
and family risk of breast cancer 107-113

p53
with erbB-2, EGFR in prognosis 261-266
paclitaxel
*see* taxol
paracrine factors
adipocyte factor inhibits mammary tumor cells 79
paracrine growth interactions
effect of fibroblasts on hormone dependent vs. independent mammary tumor cells 79
ploidy
by image cytometry, and prognosis 1-8
DNA Cytometry Consensus Conference 51-68
vs. chromosome 17 LOH, erbB-2 amplification 231-239
post-menopausal estrogens
in women at high risk for breast cancer 167-177
premalignant breast pathology
histologic and cytologic risk indicators 157-166
in risk assessment 195-210
prevention trials
in management of high risk women 195-210
progesterone
vs. MPA in inducing mammary tumors in mice 29-40
progesterone receptor
vs. ploidy and S-phase for prognosis in >25,000 patients 9-20
progestin antagonists
action of onapristone 74

progestin dependence
in MPA vs. progesterone induced mammary tumors in mice 29-40
progestins
in oral contraceptives, as breast mitogens 179-193
*see also* medroxyprogesterone acetate (MPA)
prognosis
abnormal p53, erbB-2, and EGFR 261-266
cathepsin D, uPA, and thymidine kinase vs. nodes, S-phase 74
cathepsin D, pS2, ER, and PgR in node-negative breast cancer 80
cathepsin D, pS2 in primary breast cancer 80
DNA aneuploidy vs. ER, nodes 1-8
DNA Cytometry Consensus Conference 51-68
EGF receptor by enzyme immunoassay 215-221
EGFR, S-phase, PgR, etc. in node-negative breast cancer 75
estrogen receptor vs. nodes, aneuploidy 1-8
Nottingham Prognostic Index 299-300
number of positive nodes vs. ER, aneuploidy 1-8
ploidy and S-phase in >25,000 patients 9-20
tyrosine kinase 81
uPA by ELISA in cytosols 223-229
prolactin
promotion of DMBA tumors in rats 78
prophylactic mastectomy
considerations for women at high risk 195-210
prosomal antigens
in Parsi vs. non-Parsi breast cancer 83
prostate cancer
and family risk of breast cancer 107-113
prostate tumor cells (LNCaP)
regulatory factors 79
pS2 protein
as a marker of hormone sensitivity and prognosis 80,81
in normal breast tissue 295-297
psychological distress
associated with breast cancer family history 145-155

quality of life
and estrogen replacement therapy in women at high breast cancer risk 167-177

race
and perceived risk of breast cancer 137-144
retinoic acid
stimulation of LNCaP prostate tumor cells 79
risk
histologic and cytologic indictors 157-166
psychological barriers to screening adherence 145-155
risk assessment
quantitation and applications 195-210
risk assessment and intervention
special issue 91-210
risk factors
body fat distribution 83
effects of familial prostate, ovarian, and other cancers 197-113
risk perception
associated factors 137-144

S-phase
DNA Cytometry Consensus Conference 51-68
screening
and recent trends in breast cancer incidence 97-106
effect of perceived breast cancer risk 137-144
high risk patients 91-96
psychological distress as a barrier to adherence 145-155
screening recommendations
in management of high risk women 195-210
size
*see* tumor size
somatostatin analog lanreotide
IGF-I reduction, no clinical response 84
stromelysin 3
and breast cancer invasiveness 71
surgery
timing in menstrual cycle 84

T47-D cells
ATP-cell-viability assay, taxol/doxorubicin combination 21-27
tamoxifen
*see* antiestrogens
taxol
with doxorubicin in *in vitro* sensitivity testing 21-27

thromboxane receptor antagonist EP092
growth inhibition of breast cancer cells 78
toremifene
*see* antiestrogens
tumor progression
acquisition of abnormal erbB-2, EGFR, and p53 261-266
tumor size
vs. ploidy and S-phase in >127,000 patients 9-20
tumor suppressor genes
mapping the familial breast/ovarian cancer gene BRCA1 121-135

urokinase-type plasminogen activator (uPA)
by ELISA in cytosols 223-229

vaccines for cancer
report of Workshop on Breast Cancer Research and Immunology 285-290
vincristine
in MVF induction regimen prior to high-dose therapy 291-294
vitamin $D_3$
$1,25(OH)_2D_3$ and estradiol, c-myc in MCF-7 cell regulation 77

yeast artificial chromosomes (YACs)
in mapping the familial breast/ovarian cancer gene BRCA1 121-135